Physician profile
Mohit Agarwal
NPI 1407061781
$5,289.76
in general payments reported to CMS, 2019-2025
32 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $86.40 · 2021: $537 · 2022: $640 · 2023: $1,081 · 2024: $1,158 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,914 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,914.19 |
| Education | $120.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $579.33 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $428.47 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $403.37 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Opko Pharmaceuticals, LLC | $385.12 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $323.89 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $291.12 | 2019-2024 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $268.45 | 2021-2025 | |
| Glaxosmithkline, LLC. | $238.47 | 2021-2025 | Benlysta, Jesduvroq |
| Daiichi Sankyo INC. | $237.27 | 2019-2024 | Injectafer |
| Akebia Therapeutics INC | $224.83 | 2019-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $192.38 | 2021-2024 | Acthar, Terlivaz |
| Horizon Therapeutics Plc | $189.92 | 2021-2023 | Krystexxa |
| Novo Nordisk INC | $167.50 | 2019-2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $160.84 | 2024-2025 | |
| Ardelyx, INC. | $139.54 | 2023-2025 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.07 | 2023-2025 | Jardiance |
| Baxter Healthcare | $123.64 | 2024 | |
| Alexion Pharmaceuticals, INC. | $113.98 | 2019-2024 | Ultomiris |
| Vantive US Healthcare LLC | $104.90 | 2025 | |
| Calliditas Therapeutics US INC. | $101.85 | 2022-2024 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $101.75 | 2021-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $93.32 | 2022-2024 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $60.98 | 2019-2024 | Jynarque |
| Genzyme Corporation | $44.52 | 2019 | |
| Pfizer INC. | $36.98 | 2023 | |
| Merck Sharp & Dohme LLC | $29.86 | 2024 | Prevymis |
| Cormedix INC. | $26.05 | 2025 | Defencath |
| Veloxis Pharmaceuticals, INC. | $21.98 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.61 | 2024 | Crysvita |
| Fresenius USA Marketing, INC. | $16.90 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.86 | 2019 | |
| Gilead Sciences, INC. | $13.01 | 2023 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohit Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.